about
The release of nitric oxide from S-nitrosothiols promotes angiogenesisHypoxia induces dilated cardiomyopathy in the chick embryo: mechanism, intervention, and long-term consequencesRegulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review.Angiopoietin-2 confers Atheroprotection in apoE-/- mice by inhibiting LDL oxidation via nitric oxide.Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia.Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling.Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy.Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1.Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model.Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes.Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis.A randomized double-blind placebo-controlled crossover trial of sodium nitrate in patients with stable angina INAS.Inorganic Nitrate in Angina Study: A Randomized Double-Blind Placebo-Controlled Trial.Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy.β-Cell-Specific Glucocorticoid Reactivation Attenuates Inflammatory β-Cell Destruction.Activation of proteinase-activated receptor 2 stimulates soluble vascular endothelial growth factor receptor 1 release via epidermal growth factor receptor transactivation in endothelial cells.VEGF-E activates endothelial nitric oxide synthase to induce angiogenesis via cGMP and PKG-independent pathways.Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia.Dysregulation of hydrogen sulfide producing enzyme cystathionine γ-lyase contributes to maternal hypertension and placental abnormalities in preeclampsia.Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1.Antiproliferative effects of carbon monoxide on pancreatic cancer.Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation.Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia.The role of heterodimerization between VEGFR-1 and VEGFR-2 in the regulation of endothelial cell homeostasis.Response to Letter Regarding Article, “Dysregulation of Hydrogen Sulfide (H 2 S) Producing Enzyme Cystathionine γ-lyase (CSE) Contributes to Maternal Hypertension and Placental Abnormalities in Preeclampsia”Hydrogen sulphide rescues preeclampsia-like phenotype aggravated by high sFlt-1 in placenta growth factor (PlGF) deficiencyS100P enhances the motility and invasion of human trophoblast cell lines.Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesisAntiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesisPravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trialEstablishment of porcine and human expanded potential stem cells
P50
Q33267286-179E8B78-9B6F-47C2-A78F-1B5FD69D280BQ33428551-D7C730A1-219E-4937-B163-305F48A8D771Q33930029-45D30486-01DD-4942-893F-762BC67B2DAEQ34121752-250B999B-9552-403B-9412-6EED23BF8C32Q34656275-A9C99321-227B-4787-8AFC-762E785D0C4AQ35681804-B7707C18-7406-47A8-90F6-C7462E2737A5Q35699115-55361E4D-B028-4602-862B-E1E59D0196FAQ35926413-43CAAD4B-9C67-42EA-AFDE-1AD50C449DA5Q37311066-8D9EF5AC-3F71-495E-B1AF-63C9B6C6430FQ37572203-B6EFA66B-6BD8-4076-B407-B63C47D75A31Q38426343-6C9E64AD-FD6B-49D8-ABF3-A348A12A2C5BQ38801662-993CBF6D-42F2-47AA-9BBC-C69CC67FC506Q42373731-07530BD2-12F8-4061-A3EC-6F8AAE80E373Q42497327-B71A12F8-10E3-4868-A9FF-D1A7DF5D83AEQ42943802-D366AE82-C07A-4186-913C-2AAE8F823B74Q43177653-6FD464BF-7E8A-44CB-AF65-8A58F003056FQ44054924-71A0B9FC-BE4F-41F2-8930-A1B37B93A88AQ47915288-7AD7546C-4EC5-42D1-9340-181BC0577EA3Q50963577-4E480668-8355-48AD-A041-CD75DE4589F5Q51037240-A8803764-A191-4CD6-ADBD-D4AC740410DCQ53243546-EBB21A5D-39CC-41D9-9D2A-C43FAED05611Q54312617-F9C4E48D-4AA2-426E-A845-66C9A2A1C448Q54427703-7C25A2FA-7D9D-414D-A7B5-E47C729C5E89Q54495054-149351B0-DBF1-47A4-92EA-DEE86DE180D2Q57316857-7F0C0D5A-0E1B-4AC8-9040-88F46E686212Q59897253-7A86D4A0-7C90-4B94-A967-F24D8C683286Q64947085-AC3DD3C7-86A7-450B-87A4-86BCBDE5FC91Q80199030-7BEC034B-844C-4B87-A8C5-09E3F3A2DFBBQ80410160-F6588B0F-159E-432E-9152-8EBDDEE64C35Q91245427-A9546425-4D73-407E-B2C7-2F2E62CB94F2Q92502791-502D6639-975D-463D-8EA7-6E78C553C3B5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Shakil Ahmad
@ast
Shakil Ahmad
@en
Shakil Ahmad
@es
Shakil Ahmad
@nl
Shakil Ahmad
@sl
type
label
Shakil Ahmad
@ast
Shakil Ahmad
@en
Shakil Ahmad
@es
Shakil Ahmad
@nl
Shakil Ahmad
@sl
altLabel
Shakil S Ahmad
@en
prefLabel
Shakil Ahmad
@ast
Shakil Ahmad
@en
Shakil Ahmad
@es
Shakil Ahmad
@nl
Shakil Ahmad
@sl
P106
P108
P1153
56673361100
P31
P496
0000-0002-9294-0475